One Health Basic and Translational Research Actions (INF- ACT)
The INF-ACT research programme addresses the pressing needs arising from emerging infectious diseases in humans, both as regards fundamental and translational aspects; human health is considered in a very broad context, which includes the animal world – both domestic and wild – as a potential reservoir of diseases, and environmental factors that increase the possibility of spillover, according to a "One Health" approach. The INF-ACT consortium is made up of 25 research partners from across Italy, from both the public and private sectors.
Theme: Emerging infectious diseases
Unipd project contact: Ignazio Castagliuolo
Proposing institution: University of Pavia
Implementing entity: INF-ACT - One Health Basic and Translational Research Actions addressing Unmet Needs on Emerging Infectious Diseases
Website: www.inf-act.it
PUBLIC BODIES
University
- University of Pavia
- Alma Mater Studiorum University of Bologna
- Sapienza University of Rome
- University of Bari Aldo Moro
- University of Cagliari
- University of Milan
- University of Naples Federico II
- University of Padua
- University of Siena
- University of Turin
- University of Catania
Research Organisations
- Istituto Superiore di Sanità
- Consiglio Nazionale delle Ricerche
PRIVATE BODIES
Research Organisations
- Associazione Istituti Zooprofilattici Sperimentali
- Fondazione Bruno Kessler
- Ospedale Pediatrico Bambino Gesù
- Fondazione Istituto Nazionale di Genetica Molecolare
- Fondazione Policlinico Universitario Campus Bio-Medico
- Humanitas University
- Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione s.r.l.
- Ospedale Sacro Cuore Don Calabria, Casa filiale della Congregazione dei Poveri Servi della Divina Provvidenza
- Università Cattolica del Sacro Cuore
- Università Vita Salute San Raffaele
- Istituto Ricerche Farmacologiche Mario Negri
Companies
- Soc. IRBM S.p.A.
VIDEO: Cristiano Salata presents the INF-ACT research programme at the Agorà delle Scienze of Science4All 2025
